Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-12-2016 | Retinal Disorders

Intravitreal aflibercept for myopic choroidal neovascularization

Authors: Alfredo Pece, Paolo Milani

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 12/2016

Abstract

Purpose

To assess the use of aflibercept for the treatment of subfoveal myopic choroidal neovascularization (CNV).

Methods

Thirty-two patients (33 eyes) with myopic subfoveal CNV were consecutively enrolled in this prospective open-label case series. All patients were treated with an off-label 2-mg intravitreal injection of aflibercept. After the first injection, administration of aflibercept followed an “on demand” pro re nata (PRN) regimen. The primary outcome was change in best-corrected visual acuity (BCVA) score after 12 months.

Results

Mean follow-up was 12 months, and the median number of aflibercept injections was 2.0 (range 1–4). Overall, mean BCVA improved from 0.59 ± 0.37 logMAR at baseline to 0.38 ± 0.33 logMAR at 12 months, a change of −0.21 ± 0.23 logMAR (p < 0.0001), and from 70.5 ± 18.5 to 81.1 ± 16.4 letters, a change of 10.6 ± 11.4 (p < 0.0001). Improvements were similar among patients irrespective of previous PDT. The Increase in BCVA was greater in younger patients (aged < 50 years) and those with baseline BCVA of ≤ 75 letters.

Conclusion

Intravitreal aflibercept in a PRN regimen is effective for the treatment of myopic CNV, with no apparent short-term safety effects. Treated eyes had BCVA gains after 12 months, with a median of two injections.

Wong TY, Ferreira A, Hughes R et al (2014) Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 157:9–25.e12CrossRefPubMed

Soubrane G (2008) Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 53:121–138CrossRefPubMed

Pece A, Serini P, Avanza P, Brancato R (1990) Degenerative myopia: recurrence of subretinal neovessels after laser photocoagulation. J Fr Ophthalmol 13:24–28

Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomised clinical trial-VIP report no. 1. Ophthalmology 108:841–852CrossRef

Pece A, Isola V, Vadalà M, Matranga D (2006) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina 26:746–751CrossRefPubMed

Pece A, Vadalà M, Isola V, Matranga D (2007) Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 143:449–454CrossRefPubMed

Giansanti F, Virgili G, Donati MC et al (2012) Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina 32:1547–1552CrossRefPubMed

Chan WM, Lai TY, Chan KP et al (2008) Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 28:1308–1313CrossRefPubMed

Chan WM, Lai TY, Liu DT, Lam DS (2009) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br J Ophthalmol 93:150–154CrossRefPubMed

10.

Ikuno Y, Sayanagi K, Soga K et al (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147:94–100CrossRefPubMed

11.

Mones JM, Amselem L, Serrano A et al (2009) Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 23:1275–1281CrossRef

12.

Gharbiya M, Giustolisi R, Allievi F et al (2010) Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab—a randomised controlled trial. Am J Ophthalmol 149:458–464CrossRefPubMed

13.

Lalloum F, Souied EH, Bastuji-Garin S et al (2010) Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 30:399–406CrossRefPubMed

14.

Ruiz-Moreno JM, Montero JA, Arias L et al (2010) Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 30:1609–1615CrossRefPubMed

15.

Silva RM, Ruiz-Moreno JM, Rosa P et al (2010) Intravitreal Ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 30:407–412CrossRefPubMed

16.

Vadalà M, Pece A, Cipolla S et al (2011) Is Ranibizumab effective in stopping the loss of vision for choroidal neovascularization in pathologic myopia? A long-term follow-up study. Br J Ophthalmol 95:657–661CrossRefPubMed

17.

Iacono P, Parodi MB, Papayannis A et al (2012) Intravitreal Ranibizumab versus Bevacizumab for treatment of myopic choroidal neovascularization. Retina 32:1539–1546CrossRefPubMed

18.

Lai TY, Luk FO, Lee GK et al (2012) Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 26:1004–1011CrossRef

19.

Hefner L, Riese J, Gerding H (2013) Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia. Klin Monbl Augenheilkd 230:401–404CrossRefPubMed

20.

Tufail A, Narendran N, Patel PJ et al (2013) Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology 120:1944–1945.e1CrossRefPubMed

21.

Cohen SY, Nghiem-Buffet S, Grenet T, et al. (2014) Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Jpn J Ophthalmol Nov 22

22.

Wolf S, Balciuniene VJ, Laganovska G, RADIANCE Study Group et al (2014) RADIANCE: a randomised controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121:682–692CrossRefPubMed

23.

Cohen SY (2009) Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 29:1062–1066CrossRefPubMed

24.

Wang E, Chen Y (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33:1375–1392CrossRefPubMed

25.

Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154:222–226CrossRefPubMed

26.

Stewart MW, Rosenfeld PJ, Penha FM et al (2012) Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32:434–457PubMed

27.

Heier JS, Brown DM, Chong V, VIEW 1 and VIEW 2 Study Groups et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548

28.

Ikuno Y et al (2015) Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology 122:1220–1227CrossRefPubMed

29.

Aiello LP, Brucker AJ, Chang S et al (2004) Evolving guidelines for intravitreous injections. Retina 24(5 Suppl):S3–19CrossRefPubMed

30.

Peiretti E, Vinci M, Fossarello M (2012) Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol 47:28–33CrossRefPubMed

31.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193–201CrossRefPubMed

32.

Calvo-Gonzales C, Reche-Frutos J, Donate J et al (2011) Intravitreal Ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 151:529–534CrossRef

33.

Gharbiya M, Cruciani F, Parisi F et al (2012) Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 9(68):1068–1072CrossRef

Title: Intravitreal aflibercept for myopic choroidal neovascularization
Authors: Alfredo Pece
Paolo Milani
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 12/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-016-3396-9

At a glance: The STEP trials

Springer Medicine

Intravitreal aflibercept for myopic choroidal neovascularization

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2016

Effects of intravitreally injected Fc fragment on rat eyes

Ophthalmic Pathology, Yanoff M and Sassani JW (2015), (print version with Expert Consult online access of e-content or kindle/e-book format). ISBN:978-1-4557-2874-9 Elsevier

Giant cell arteritis: ophthalmic manifestations of a systemic disease

The diameter response of retinal arterioles in diabetic maculopathy is reduced during hypoxia and is unaffected by the inhibition of cyclo-oxygenase and nitric oxide synthesis

Osmotic expression of aldose reductase in retinal pigment epithelial cells: involvement of NFAT5

Prevention of re-obstruction in watery eye treatment: three-flap technique in external dacryocystorhinostomy